Legal & General Group Plc increased its position in Johnson & Johnson (NYSE:JNJ) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,824,479 shares of the company’s stock after acquiring an additional 173,991 shares during the period. Johnson & Johnson makes up about 1.3% of Legal & General Group Plc’s investment portfolio, making the stock its 4th biggest position. Legal & General Group Plc owned approximately 0.48% of Johnson & Johnson worth $1,771,956,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Selective Wealth Management acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $105,000. Fusion Family Wealth LLC grew its holdings in Johnson & Johnson by 621.4% during the 2nd quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock valued at $123,000 after buying an additional 870 shares during the last quarter. Ifrah Financial Services Inc. acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $203,000. First Capital Advisors Group LLC. acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $207,000. Finally, Jentner Corp acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $208,000. Institutional investors and hedge funds own 66.56% of the company’s stock.

JNJ has been the topic of a number of analyst reports. Citigroup lowered their target price on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a report on Wednesday, January 2nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Tuesday, November 20th. Morgan Stanley set a $140.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Thursday, December 20th. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $152.00 target price (down previously from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $142.81.

Shares of Johnson & Johnson stock opened at $137.60 on Friday. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The firm has a market cap of $369.17 billion, a price-to-earnings ratio of 16.82, a price-to-earnings-growth ratio of 2.13 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.02. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The company had revenue of $20.39 billion for the quarter, compared to analyst estimates of $20.27 billion. During the same quarter in the prior year, the company posted $1.74 EPS. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 8.57 earnings per share for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has authorized a share repurchase program on Monday, December 17th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 1.5% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th were paid a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date was Monday, February 25th. Johnson & Johnson’s dividend payout ratio is presently 44.01%.

WARNING: This piece was reported by Marea Informative and is the sole property of of Marea Informative. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Trading Ex-Dividend Strategy

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.